From FDG and beyond: the evolving potential of nuclear medicine.
Kenji HirataKoji KamagataDaiju UedaMasahiro YanagawaMariko KawamuraTakeshi NakauraRintaro ItoFuminari TatsugamiYusuke MatsuiAkira YamadaYasutaka FushimiTaiki NozakiShohei FujitaTomoyuki FujiokaTakahiro TsuboyamaNoriyuki FujimaShinji NaganawaPublished in: Annals of nuclear medicine (2023)
The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [ 177 Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.
Keyphrases
- positron emission tomography
- pet ct
- computed tomography
- pet imaging
- artificial intelligence
- machine learning
- prostate cancer
- deep learning
- magnetic resonance imaging
- big data
- high resolution
- randomized controlled trial
- blood pressure
- cardiac surgery
- mesenchymal stem cells
- amino acid
- stem cells
- benign prostatic hyperplasia
- bone marrow
- dual energy
- type diabetes
- fluorescence imaging
- blood glucose